All donors on dopamine therapy were co-treated with peripheral DOPA decarboxylase inhibitors (carbidopa or benserazide), and four PD donors were on entacapone, a peripherally acting COMT inhibitor. The gene discussed is COMT; the disease is Parkinson disease.